Total pharma industry venture financing deals in Q1 2019 worth $3.37bn were announced in the US, according to GlobalData’s deals database.

  • Embed this chart

    Embed this chart into your website

    Copy and paste the code below into your website to display the chart.

The value marked a decrease of 4.8% over the previous quarter and a drop of 12.7% when compared with the last four-quarter average of $3.86bn.

The US held a 68.3% share of the global pharma industry venture financing deal value that totalled $4.93bn in Q1 2019.

In terms of deal activity, the US recorded 163 deals during Q1 2019, marking a decrease of 4% over the previous quarter and a drop of 4.1% over the last four-quarter average.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData

The US pharma industry venture financing deals in Q1 2019: Top deals

The top five pharma industry venture financing deals accounted for 26.5% of the overall value during Q1 2019.

The combined value of the top five pharma industry venture financing deals stood at $890.7m, against the overall value of $3.37bn recorded for the quarter. The top announced pharma industry venture financing deal tracked by GlobalData in Q1 2019 was Aisling Capital, American International Group, Cormorant Capital, Hercules Capital, Kohlberg Kravis Roberts & Co, Perceptive Advisors, Sequoia Capital Operations and Viking Global Investors’ $299.2m venture financing of BridgeBio Pharma.

In second place was the $191m venture financing of Maze Therapeutics by Alexandria Venture Investments, ARCH Venture Partners, Casdin Capital, Foresite Capital Management, GV Management and Third Rock Ventures and in third place was Biotechnology Value Fund, Curative Ventures, Driehaus Capital Management, EcoR1 Capital, Eventide Asset Management, Foresite Capital Management, Nextech Invest, Orbimed Advisors, RA Capital Management, The Column Group, Tichenor Ventures, Topspin Fund and Vida Ventures’ $150m venture financing of Peloton Therapeutics.

The $135m venture financing of Beam Therapeutics by Altitude Life Science Ventures, ARCH Venture Partners, Cormorant Asset Management, Eight Roads Ventures, F-Prime, Omega Fund Management and Redmile Group and Frazier Healthcare Partners, Lilly Asia ventures, New Leaf Venture Partners, Orbimed Advisors, Versant Venture Management and Vivo Capital’s venture financing of Passage Bio for $115.5m held fourth and fifth positions, respectively.

This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Country and industry are defined according to the headquarters and dominant industry of the target firm. The term ‘acquisition’ refers to both completed deals and those in the bidding stage.

GlobalData tracks real-time data concerning all merger and acquisition, private equity/venture capital and asset transaction activity around the world from thousands of company websites and other reliable sources.

More in-depth reports and analysis on all reported deals are available for subscribers to GlobalData’s deals database.